Best NAD+ Source: 40 Percent of the Score Is One Test

Best NAD+ source is a question that cannot be answered honestly without stating the weighting first, because the ranking is entirely determined by what you decide to weight. A rubric that treats price, purity and shipping speed as roughly equal produces one order. A rubric built around the failure this market has actually produced produces a different one, and the second is the rubric below.

Forty of the hundred points sit on a single assay. That is not a rhetorical flourish. It reflects that identity failures, purity failures and shipping failures in this market are recoverable annoyances, while the failure FDA documented for NAD+ specifically sent people for medical treatment, and it is detected by a test that most certificates in this category do not include.

The vendor scored in detail below is the one whose published material we can quote, and it is scored with an open item rather than a tidy total.

The weighting, published before the result

Five components, a hundred points, and a justification for each weight. Anyone who disagrees with the ranking can disagree with a number here rather than with a conclusion.

Two structural notes. Endotoxin and grade are scored together because they are the same question asked at two points in the chain: what the material was released as, and whether anyone measured the consequence. And 65 of the 100 points require a document tied to a lot number, which means a seller with no batch certificate has a ceiling of 35 before anything else is considered.

Why one assay outweighs the other four components combined

The justification is a single agency notice, content current as of 30 October 2024, and it is worth reading closely because it is unusually specific. FDA stated it is aware of compounders using food grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products, and that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins. It then reported adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment, and assessed those reactions as consistent with excessive levels of endotoxins.

Note what is absent from that account. Nobody was sold the wrong compound. No purity failure is described. The material was NAD+ and the harm travelled alongside it, which is exactly the case a purity figure is blind to: endotoxins are heat stable lipopolysaccharide fragments measured in endotoxin units by a dedicated assay, and a reversed phase HPLC detector is not looking for them at any wavelength.

The test is neither exotic nor expensive relative to the material. FDA maintains a guidance document on pyrogen and endotoxins testing, revised in March 2026, and independent comparisons of the available assay formats have been published in the pharmaceutical quality literature, including work on recombinant alternatives to the traditional lysate reagent. A supplier without an endotoxin result has made a decision about scope, and weighting that decision at 40 points is the rubric taking it seriously.

The best NAD+ source on this rubric, and the four it beats

Categories are scored on their structural characteristics, which is the most a category can be scored on. The disclosed vendor is scored individually, with the open component shown as a range rather than resolved by assumption.

1. Disclosed vendor: Ascension Peptides, 60 to 100 depending on one answer

Identity and purity score at the top of the range: certificates from two independent laboratories per lot, Kovera Labs and MZ Biolabs, published as a catalogue wide practice rather than as a one off document. Price transparency scores fully: $104.00 list, $52.00 with the code PEPTIDEDECK, $5.20 per 100 mg, quantity tiers of 3, 5 and 10 percent published against list rather than implied. Custody scores on a same day dispatch commitment before 2pm CST, which is a promise only held stock supports. Claim hygiene scores on research use framing with no dosing content published.

The endotoxin component is open. We have not seen a certificate for a specific NAD+ lot and we will not assume in either direction, so the honest score is 60 out of 60 on everything we can check, plus 0 to 40 on the component that decides the ranking. That is a deliberately uncomfortable way to present a result and it is the accurate one. Send the question before ordering; the wording is in our purchase checklist.

2. Domestic storefront with a product line certificate, around 45

This is the largest category in the market and it fails in a specific way. The certificate exists, the laboratory is real, the analysis was performed, and the document is not tied to a lot. On this rubric that costs most of the 25 identity points, because batch matching is what converts analysis into evidence about your vial, and it costs the endotoxin component outright since a product line document is almost never scoped to include it. Custody and price transparency remain available.

3. Compounding channel, unscored but structurally strong on documents

Not a source a private buyer can use directly, and worth placing because its documentary requirements are the strictest here. Section 503A requires that bulk drug substances used in compounding be accompanied by a valid certificate of analysis and be manufactured by an establishment registered with FDA under section 510. Nicotinamide Adenine Dinucleotide (NAD) sits in category 1 of the nominated bulk substances list, which means non enforcement during evaluation and not approval. The regulatory detail is in our explainer on NAD+ without a prescription.

4. Overseas bulk broker, around 20

Lowest unit price in the market and the weakest position on 65 of the 100 points. Documents are typically product line rather than lot matched, grade is the variable the channel is least motivated to clarify since the same powder serves food, cosmetic and research markets, and custody scores poorly because an import adds inspection, delay and a jurisdiction problem. Price transparency is often genuinely good, which is not enough to move the total.

5. Social platform and forum resellers, under 10

There is no entity to hold to anything, which removes custody and claim hygiene as well as the analytical components. The recurring pattern is a forwarded certificate that is entirely genuine, issued by a real laboratory for a real lot, and simply not the lot being sold. The document survives inspection because there is nothing wrong with the document. What is missing is the chain connecting it to anything you will receive.

What happens to the ranking if you disagree with the weights

Publishing a rubric means it can be argued with, so here is the sensitivity. Drop the endotoxin component to 15 points and redistribute the 25 across price and dispatch, and the overseas broker climbs while the top of the table barely moves, because the disclosed vendor already scores well on the redistributed components. Drop it to zero and the ranking becomes a price list, which is what most comparison pages for the best place to buy NAD+ actually are. A page that names the best source for NAD+ without telling you what it measured has published a preference rather than a method.

The weight is defensible only if you accept that contamination is the live risk for this substance rather than misidentification. That premise comes from an agency notice describing real adverse events, not from a theoretical risk model, which is why we are comfortable putting 40 points on it and equally comfortable showing you what changes if you are not.

A note on what a good source does not buy you

Scoring suppliers well is a supply chain exercise and it does not upgrade the evidence behind the substance. The settled science is cellular: NAD+ is a redox cofactor consumed and regenerated continuously, a substrate for enzyme families whose activity tracks its availability, and the subject of a substantial review literature on its role in cellular processes during ageing. That is tier one evidence for a biochemical claim.

It is not evidence for a clinical one. No injectable NAD+ product has been assessed by a United States regulator for quality, safety or efficacy, clinics market infusions for indications we report without adopting, and the best supplier in this ranking still sells a research chemical. Keeping those two tiers apart is the actual discipline; the rubric above is just bookkeeping underneath it.

For the same market cut other ways, see our channel comparison, our listing anatomy guide and our transaction walkthrough. The equivalent exercise for a peptide, where the weighting comes out differently because the risk profile does, is in our retatrutide source ranking.